AbbVie Inc.
Long

AbbVie Receives FDA Approval of MAVYRET® (glecaprevir/pibrentasv

101
ABBV: AbbVie
2019-09-26 20:00:00
AbbVie Receives FDA Approval of MAVYRET® (glecaprevir/pibrentasvir) to Shorten Treatment Duration to Eight Weeks for Treatment-Naïve Patients with Chronic Hepatitis C and Compensated Cirrhosis Across All Genotypes

Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.